disseminated disease by chest X-ray, isotope scanning and full blood investigations. Only a small number of patients will be found to have evidence of dissemination, but it is still an essential part of clinical staging (Forrest et al. 1980 , Coombes et al. 1980 . At the present time the role of the surgeon in treatment is limited. He will remove the tumour to confirm the diagnosis. Immediate histological examination is essential and with the diagnosis established a plan of treatment must now be made. The surgeon has only one objective, to treat the patient in such a way that he will give the maximum chance of freedom from local recurrence both in the breast and in the regional lymph nodes. If the surgeon considers that removal of the breast will give the best and perhaps the only chance of preventing local recurrence, then every effort should be made to carry out an anatomically adequate excision. The axilla must be dissected since not only will involved nodes be removed but the pathological stage will then be known. In all other cases where the surgeon decides that the removal of the breast will not affect either the length of survival or the incidence of local recurrence, limited surgery is indicated. Mutilation without hope has no place in the treatment of breast cancer.
When it is considered that there is even the slightest possibility of a mastectomy the surgeon must discuss the implications of the operation with the patient. Until recently the support of the patient has often been neglected.
The surgeon should always have available the help of a mastectomy counsellor. A nurse specialist attached to the clinic will advise the patient about the types of prosthesis available and the suitability of clothes and swimsuits.
After the initial treatment by surgery, the further management of the patient should be discussed with the medical oncologist and the radiotherapist since the problem now is the prevention of local recurrence and dissemination. However, routine radiotherapy or adjuvant cytotoxic therapy to node-positive cases may not increase survival. There are many factors which need to be considered in the planning of prophylactic or adjuvant therapy: for example, the histology of the tumour, the presence or absence of vascular invasion or lymphatic permeation and, perhaps most significant, the oestrogen receptor status (Nealon et al. 1979 ,Sampat et al. 1977 ,Lee 1979 . It is here that the medical oncologist and the radiotherapist have perhaps a more important role to play than the surgeon. The role of the surgeon in locally advanced disease, both with or without evidence of dissemination, is limited only to establishing the diagnosis, and the plan of treatment should be made by consultation with other members of the unit. o141-fJ768j120838-fJ3j$01.00/0
In the follow up period it has always been a tradition that the patient should remain under the care of the surgeon and indeed the patient always expects to see 'her surgeon'. This has often been impractical because of the sheer number of cases. The combined breast clinic may provide a satisfactory solution. It will allow the surgeon to supervise the follow up with the other members of the team.
Thus, although the surgeon should continue to play a major part in the management of the patient with breast cancer, he should be given the opportunity to work with a team and likewise should give them the opportunity to work with him.
W P Greening Consulting Surgeon Royal Marsden Hospital. London
Drug trials in rheumatoid arthritis
The practice of rheumatology has become flooded in the last few years by the arrival of large numbers of compounds which are capable of reducing inflammation and taking away the pain of arthritis. These drugs are largely symptomatic in their mode of action in that they do not interfere with the underlying disease process. Disease-modifying agents with slow onset of action that may not be anti-inflammatory in conventional tests have been available. Historically, the first of these was gold and, more recently, penicillamine has appeared to rival this compound. Both these drugs are frequently toxic, gold causing proteinuria, blood abnormalities and skin rashes, while the use of penicillamine leads to a myriad of reversible side effects which include virtually all systems of the body. A good example of this is dermatomyositis, described by Fernandes et al. (1977) and confirmed by the case report in Journal of the Royal Society of Medicine Volume 73 December 1980 839 this issue (Wojnarowska, p 884). Azathioprine has also been looked at, but this too has serious side effects (possibly mutagenicity and carcinogenicity) which prevent its use in average rheumatoid arthritics, unless they are suffering from very severe forms of arthritis. Other immunosuppressives such as cyclophosphamide and 6mercaptopurine have also had their advocates, but it is generally considered that these drugs are too toxic to warrant general use in rheumatology. The search has therefore begun for other compounds which would seem to offer the benefit of gold and penicillamine without the toxic manifestations. These compounds might then be used in a preventive way in early disease to stop the progression of erosive changes.
The implication has arisen that alclofenac (Berry et al. 1978 ) and, more recently, fenclofenac (Berry et af. 1980 )have a largely long-term, rather than short-term, effect in the clinical trials that have been carried out. This work needs confirmation, particularly the work on fenclofenac. Other newer compounds are also now being studied and these include Clozic (ICI) and an oral form of gold -auranofin.
The assessment of these compounds is extremely difficult. The purpose of using a diseasemodifying antirheumatic drug is to induce remission. Decker (1980) has laid down criteria for drug-induced remission. He mentions that a patient should exhibit four of the following six features: no pain, no tenderness, no swelling, no fatigue, morning stiffness of less than 15 minutes, and an ESR that falls below 20 in a male and 30 in a female. These are sensible therapeutic objectives for drugs in this group.
The quantification of disease modification is extremely difficult. There is some evidence from Duncan (1980) that osteoclasts are the causative agent in producing erosions and there is also a certain amount of evidence implying that osteoclasts are monocyte derived, but monocyte function is difficult to assess in vitro or in vivo. The actual quantification of the radiological changes is also unsatisfactory. Gelman (1980) has suggested that erosions should not be counted but whole diseased joints assessed as an index. He used a high density single spot tube as a means of magnification. This apparatus is expensive but cannot take into account variation of joint space with position.
The only worker, so far, who has been able to show any slowing down of erosions is Larsen in his analysis of the levamisole Eular study in the Dpenicillamine treated group (Larsen et al. 1979) . Much work has been carried out on the possibility of using blood and immune measures in arthritis. These appear to be objective measures. Complement, rheumatoid factor, antibodies, anti-DNA, circulating immune complexes and immunoglobulin concentrations have all been studied. The only measures which seem to be of real value here are the ESR fall, the haemoglobin improvement and, possibly, the C-reactive protein fall. No other laboratory measures seem to reflectclinical disease change.
What matters to the patient is the ability of a drug to produce functional improvement. The problem of functional assessment is that in some way the patient's own ability to influence such measures must be taken into account. High-power scores of function take a long time to perform. Functional indices, such as walking time, are so liable to subjective variation that, in my view, they should be discarded from clinical trials.
All drug trials should consider the safety of the drug concerned. One area of considerable importance has been the investigation of mutagenicity and carcinogenicity. The Committee on Safety of Medicines in the UK has laid down that such data are required on all compounds that will be marketed in the future. The Ames' test occasionally appears to give false positives and false negatives but, nevertheless, seems to be a reasonable means of assessing compounds. It is of interest that gold is not mutagenic, but azathioprine is both mutagenic and carcinogenic; data are still awaited on levamisole and penicillamine. It is also important to assess metabolites which may be mutagenic even though the parent compound may be free from this problem.
For toxicity screening, large numbers of patients should be studied. However, the chance of picking up a side effect that occurs once in 10000 patients exposed to a drug is small unless such a study is carried out in at least 100000 patients. Therefore, the rarer side effectswill not be observed until large studies are performed. There is consequently a need for long post-marketing toxicity studies and probably we should all be more vigilant in the way we report to the Committee on Safety of Medicines. Perhaps the use of tissue markers may help in predicting which patients will develop side effects. However, a full HLA tissue screen is now very expensive and therefore its use can be considered only as a research tool.
The best way of assessing a new compound is to use the least number of measures that will give the most information. Umbenhauer (1980) feels that the main factors in the evaluation of a new compound are the overall progress of the patient and, especially, pain relief and the articular index. To these may~added the fall in ESR, the rise in haemoglobin and the fall in C-reactive protein for the disease-modifying drugs. Other measures may be important in the assessment of safety rather than efficacy. X-rays do not seem to be helpful in the assessment of new compounds. It is to be hoped that research will lead to the identification of other measurable factors that may be correlated with clinical change.
Hedley Berry Consultant in Rheumatology & Rehabilitation
King's College Hospital. London whilst another admits that even in his experienced hands some ears are totally deafened by surgery; some insist that silastic is essential for success. while others find it useless; some extol the virtues of the Paiva flap. whilst others say that it never survives; some obtain 90% dry cavities, whilst the majority have to be content with much fewer. The only measure of agreement is that in no circumstances will anyone mention the word hearing aid, and the undoubted benefit of some of the techniques has to be balanced against the disadvantages to those who as a result of surgery are unnecessarily deaf. disfigured or even dead. The risk of recurrence of cholesteatoma after combined approach tympanoplasty, especially in children. has led many surgeons to reserve intact meatus operations for those patients who agree to a second stage operation two or three years later to deal with recurrent disease. This may be satisfactory in centres where follow-up arrangements are above average, but in most departments a sizeable number of patients cannot be traced after this period. Some of these will be suffering from a life-threatening condition hidden even to the all-perceiving eye of the CT scanner, often without being aware of this. Attempts to reduce the recurrence rate by modifications, such as the mobile bridge technique, seem to be no more successful (S H Richards. 1979. personal communication) . Combined approach techniques are justified where there is only mucosal disease or a deep pocket in the sinus tympani. but the risks to the cochlea of even a simple myringoplasty must not be underestimated. Smyth (1977) has been frank about the incidence of sensorineural loss following surgery; he found that there were nine dead ears in 772 patients undergoing transcanal tympanoplasty and four in 631 undergoing operations to obliterate the mastoid cavity and reconstruct the tympanum. Approximately 4% of 621 patients had a severe hearing loss after combined approach tympanoplasty and the risks were particularly high. some 6%. in patients undergoing operations when the ossicular chain was intact. In most hands the risks will be higher than this and if patients were as concerned about the viability of their cochlear apparatus as they are about the continuity of their facial nerves, the law courts would be even busier than they are. It seems inevitable that damage to the facial nerve is more likely to occur with such complicated operations, and even Schuknecht and his colleagues admit to permanent facial palsies as a result of this type of surgery (Lee & Schuknecht 1971) .
Surgeons on the whole are a conservative body and do not adopt newly-described techniques until they are shown to have considerable merit. On the other hand, some seem slow to abandon these when they are proved to be unsatisfactory. Despite
